
    
      This is a single center feasibility imaging study in patients with diffuse large B-cell
      lymphoma (DLBCL) or B-cell Lymphoma, Unclassifiable with features between DLBCL and Burkitt's
      (BCLU). Study participants will undergo PET/MRI of the whole body with 68Ga citrate.

      The study will include at least 5 patients with double hit lymphoma and 5 patients with DLBCL
      with an additional 5 more patients as expansion once the dose level has been established.
      Patients with DLBCL will be included once an optimal dose level for the resolution of cancer
      lesions has been established.
    
  